-- Trial expected to commence in third quarter; Results to be reported by year end ...
2017: a year of very significant reinforcement of the cash position (€274M at 12.31.2017), ...
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned ...
